Avenue Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch ATXI and buy or sell other stocks, ETFs, and their options commission-free!About ATXI
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain.
CEOAlexandra MacLean
CEOAlexandra MacLean
Employees4
Employees4
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2015
Founded2015
Employees4
Employees4
ATXI Key Statistics
Market cap61.49M
Market cap61.49M
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume12.36M
Average volume12.36M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$1.85
52 Week high$1.85
52 Week low$0.20
52 Week low$0.20
Stock Snapshot
As of today, Avenue Therapeutics(ATXI) shares are valued at $2.73. The company's market cap stands at 61.49M.
On 2025-12-17, Avenue Therapeutics(ATXI) stock opened at —, reached a high of —, and a low of —.
The Avenue Therapeutics(ATXI)'s current trading volume is 0, compared to an average daily volume of 12.36M.
During the past year, Avenue Therapeutics(ATXI) stock moved between $0.20 at its lowest and $1.85 at its peak.
During the past year, Avenue Therapeutics(ATXI) stock moved between $0.20 at its lowest and $1.85 at its peak.
People also own
Based on the portfolios of people who own ATXI. This list is generated using Robinhood data, and it’s not a recommendation.